Divalproex Sodium Tablet, Delayed Release
Product Images NDC 51655-365

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 51655-365). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (39cef9df 868d 4963 B0a7 7f146275442f 01)

Chemical structure of the active ingredient Divalproex Sodium showing its molecular framework with carboxylate groups and alkyl chains, depicted as a repeating unit (polymer) with sodium ions present.*

FDA Label Image

Image (39cef9df 868d 4963 B0a7 7f146275442f 02)

A bar chart comparing two studies over different years (YRS). It shows percentage outcomes for placebo (PBO) and Divalproex Sodium (DVPX). In Study 1, PBO is at 26% and DVPX at 60%. In Study 2, PBO is at 29% and DVPX at 58%. The y-axis represents percentage values from 0% to 70%.*

FDA Label Image

Image (39cef9df 868d 4963 B0a7 7f146275442f 03)

A cumulative percentage curve graph depicting the percent reduction in Clinical Psychiatric Scale (CPS) rate versus percent of patients for Divalproex Sodium and placebo groups. The vertical axis shows percent reduction in CPS rate from -100% to 100%, indicating worsening to improvement, while the horizontal axis shows the percentage of patients from 100% to 0%. The solid line represents Divalproex Sodium, and the dashed line represents placebo outcomes.*

FDA Label Image

Image (39cef9df 868d 4963 B0a7 7f146275442f 04)

A line graph comparing the percentage reduction in CPS rate between high and low doses of a medication. The x-axis represents the percentage of patients, while the y-axis shows the percentage reduction in CPS rate, ranging from -100% to 100%. Two curves indicate patient response distribution for high dose (solid line) and low dose (dashed line). The graph includes labels for improvement and worsening directions.*

FDA Label Image

Image (39cef9df 868d 4963 B0a7 7f146275442f 05)

A bar chart comparing placebo and Divalproex Sodium in two studies. The y-axis shows numerical values, with placebo bars higher than Divalproex Sodium in both Study 1 and Study 2, indicating comparative outcome measurements.*

FDA Label Image

39cef9df 868d 4963 B0a7 7f146275442f 06

FDA Label Image

Label (51655 365 52 Master Bottle Label Approval Rev A 05 20)

Label for Divalproex Sodium delayed release tablets, USP, 250 mg strength. The bottle contains 30 tablets for oral use, labeled Rx only. The label includes storage instructions at 20°-25°C (68°-77°F), a barcode, and manufacturer information for Northwind Pharmaceuticals, LLC, Indianapolis, IN.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.